Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
| Autor: | Yoshihiko Taniguchi, Hidekazu Suzuki, Takafumi Yanase, Tomonori Hirashima, Akihiro Tamiya, Motohiro Tamiya, Satoshi Tanizaki, Kinnosuke Matsumoto, Kiyonobu Ueno, Hayato Kawachi, Junji Uchida, Yoshinobu Matsuda, Shinji Atagi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Performance status business.industry Hazard ratio medicine.disease Ramucirumab Metastasis 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Docetaxel 030220 oncology & carcinogenesis Internal medicine medicine Malignant pleural effusion Original Article Lung cancer business neoplasms medicine.drug Brain metastasis |
| Zdroj: | Transl Lung Cancer Res |
| ISSN: | 2226-4477 2218-6751 |
| Popis: | Background Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effect on factors such as Eastern Cooperative Oncology Group (ECOG) performance status (PS) and metastatic sites is still unknown. Methods We recruited NSCLC patients who received DOC plus RAM in four medical facilities in Japan from June 2016 to March 2020. We retrospectively investigated the overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) of DOC plus RAM and conducted univariate and multivariate analyses using PFS as a dependent factor. Patients were followed up until June 30, 2020. Results A total of 237 patients were consecutively enrolled. For all patients, the ORR, DCR, and median PFS were 25.2%, 63.9%, and 4.5 months, respectively. The ORR and DCR for malignant pleural effusion (MPE), lung metastasis, and liver metastasis were 7.7% and 53.8%, 30.3% and 77.5%, and 48.6% and 71.4%, respectively. In the multivariate analysis, MPE, lung metastasis, and liver metastasis were not prognostic factors for poor PFS. However, ECOG-PS 2 or more [hazard ratio (HR): 1.66, 95% confidence interval (CI): 1.14-2.40, P=0.008] and brain metastasis (HR: 1.71, 95% CI: 1.23-2.37, P=0.001) were significant and independent factors associated with shorter PFS. Conclusions DOC plus RAM could be an optimal therapy for previous treated NSCLC patients with lung and liver metastasis, and furthermore, should be used carefully for patients with poor ECOG-PS or brain metastasis. Keywords Docetaxel and ramucirumab; non-small cell lung cancer (NSCLC); metastatic site; poor performance status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|